EP16.03-012 Novel Human-derived EML4-ALK Fusion Cell Lines Identify Ribonucleotide Reductase RRM2 As a Target of Activated ALK in NSCLC

Echinoderm microtubule-associated protein-like 4 (EML4)-Anaplastic Lymphoma Kinase (ALK) rearrangements occur in 7% to 10% of lung adenocarcinomas and are targets for treatment with tyrosine kinase inhibitors. Here we have developed three novel EML4-ALK-positive patient-derived Non-Small-Cell-Lung-Cancer (NSCLC) cancer cell lines, CUTO8 (variant 1), 9 (variant 1), and 29 (variant 3), and included a fourth ALK-positive cell line YU1077 (EML4-ALK variant 3) to study ALK-positive signaling and responses.